Press releases

STORM Therapeutics appoints Dr. Angus Lauder as Director of Business Development

20 April 2020, Cambridge, UK: STORM Therapeutics, the biotechnology company focused on the discovery of small molecule therapies modulating RNA epigenetics, today announces the appointment of Dr. Angus Lauder as Director of Business Development with immediate effect.

Dr. Lauder has over 15 years of business development experience working with biotech and pharmaceutical companies, and academia. Previously, Dr. Lauder was Associate Director Business Management & Transactions at Cancer Research UK Commercial Partnerships (formerly Cancer Research Technology) where he led the deal team in major drug discovery alliances including CRT’s biggest and highest value drug discovery alliance deal to date, with Celgene. Dr. Lauder also brings a wealth of experience negotiating large numbers of licenses and collaborations as well as in the formation of company spin-outs including Mission Therapeutics and Azeria Therapeutics.

Commenting on today’s appointment, Dr Keith Blundy, CEO of STORM Therapeutics said: “As the leading company tackling disease through modulating RNA modifying enzymes, STORM is fast progressing in its preclinical work and became the first Company in the world to demonstrate in vivo and proof of concept efficacy in animal models and is on course to enter the clinic in 2021.

“I would like to welcome Angus to the team as we focus on developing a unique platform and pipeline, and set the stage for future long-term growth. He brings a strong track record of delivering complex deals and brings extensive drug discovery and technology development knowledge.”

Dr Angus Lauder commented: “STORM is a pioneer in RNA epigenetics with a mission to tackle disease through modulating RNA modifying enzymes. I look forward to working closely with the management team in shaping the next chapter in STORM’s evolution and future success.”

Dr Lauder has PhD in Molecular and Cellular Biology from Institute of Cancer Research, University of London, before undertaking post-doctoral research studies at the MRC Laboratory of Molecular Biology in Cambridge.

For further information:

STORM Therapeutics Ltd
Keith Blundy
T: +44 (0)1223 804174

Optimum Strategic Communications
Mary Clark, Eva Haas, Shabnam Bashir
Tel: +44 (0)203 950 9144



STORM Therapeutics, founded in 2015, is a University of Cambridge spin-out translating the ground-breaking work of Professors Tony Kouzarides and Eric Miska in RNA epigenetics into the discovery of first-in-class drugs in oncology and other diseases. Storm is the leading company tackling disease through modulating RNA modifying enzymes and is developing a unique platform and pipeline to address these enzyme classes, including RNA methyltransferases.

STORM is backed by blue chip investors Cambridge Innovation Capital, M Ventures, Pfizer Ventures, Taiho Ventures LLC, Seroba Life Sciences and IP Group, who share the team’s ambitions to build a world-leading company in the field.